A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the proposed study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene; Calcitriol

Criteria

Inclusion Criteria:

• Must have a diagnosis of nail psoriasis in fingernail or toenails

• History of plaque psoriasis or psoriatic arthritis

• Target nail will be KOH negative for dermatophyte fungus

• Must give written informed consent prior to study procedures being conducted, also give consent to the release and use of protected health information (PHI)

• Between the ages of 18 and 85 years old

• Candidate for topical therapy in the opinion of the investigator

Exclusion Criteria:

• Males and Females unable to practice effective contraception throughout the study

• Unable to comply with the protocol

• Nursing mothers, pregnant women, and women planning to become pregnant while in this study

• Patients with erythrodermic or pustular psoriasis

• Sustained treatment to target fingernail within 6 months prior to screening

• History of trauma or surgery to target fingernail

• History of disease known to affect nails such as lichen planus, onychomycosis

• History of systemic psoriasis therapy for less than 6 months